Within the ER−PR-negative (PR–) subset, 34% (15/44) of HER2– tumors (triple-negative breast cancer, TNBC) were AR+, and among HER2-positive tumors, 86% (12/14) were AR+. Here, ERBB2 is linked to triple-negative breast carcinoma.